Results 11 to 20 of about 5,819 (161)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]
Clin Pharmacol TherThiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M +18 more
europepmc +2 more sources
Pharmacogenetics and Genomics, 2010 The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g. Crohn’s disease and rheumatoid arthritis) and of organ transplant recipients. As inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine require intracellular activation, catalyzed by ...
Gianluigi Zaza +11 more
openaire +7 more sources
Therapeutic Advances in Gastroenterology, 2020 Aims: Thiopurines are believed to increase cancer risks, but data from Asian patients are sparse. We determined the risks of malignancies in thiopurine users with inflammatory bowel disease (IBD) or other indications from Hong Kong. Methods: All patients
Kelvin Y. C. Zheng +6 more
doaj +1 more source
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
Brazilian Journal of Oncology, 2021 The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj +1 more source
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. [PDF]
PLoS ONE, 2013 ObjectiveInflammatory bowel disease (IBD) is commonly treated with thiopurines such as azathioprine and mercaptopurine for the maintenance of remission.
Jianfeng Gong +6 more
doaj +1 more source
Squamous cell carcinoma and Crohn's disease: a sometimes-challenging diagnosis
Future Science OA, 2023 Aim: Non-melanoma skin cancers are more common in people with inflammatory bowel disease. However, these tumors can rarely mimic a cutaneous manifestation of the disease, which delays diagnosis and clouds prognosis.
Mona Boudabbous +9 more
doaj +1 more source
Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?
Frontiers in Medicine, 2019 Thiopurines are a cheap, effective treatment option in the management of inflammatory bowel disease (IBD). However, with the growing choice of targeted therapies available, as well as the well-documented toxicities of thiopurines, the role of thiopurines
Raphael P. Luber +3 more
doaj +1 more source
The Thiopurine Tale: An Unexpected Journey [PDF]
Journal of Crohn's and Colitis, 2022 Abstract Exactly 70 years ago [1951] mercaptopurine was discovered by Gertrude Elion as a novel treatment option for acute leukaemia. A total of three thiopurines (also thioguanine [1950] and azathioprine [1957]) were developed over time.
Femke Crouwel +2 more
openaire +3 more sources
Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID) [PDF]
Intestinal Research, 2015 Background/AimsFor decades, thiopurines have been the mainstay of inflammatory bowel disease (IBD) treatment and will play an important role in the future.
Kang-Moon Lee +5 more
doaj +1 more source
Metabolites, 2022 Thiopurine drugs are part of the therapeutic armamentarium for pediatric patients suffering from inflammatory bowel disease (IBD) and acute lymphoblastic leukemia (ALL).
Martina Franzin +8 more
doaj +1 more source